Liquid pasteurization of an immunoglobulin preparation without stabilizer: Effects on its biological and biochemical properties

被引:17
作者
Bridonneau, P
Marcilly, H
VernoisMartin, M
Goigoux, P
Bourdel, V
Laulan, A
Deramoudt, FX
Desmadril, M
Sitbon, M
Basuyaux, B
Steinbuch, M
Schmitthaeusler, R
机构
[1] FDN NATL TRANSFUS SANGUINE, RECH & DEV, LES ULIS, FRANCE
[2] UNIV ORSAY, ENZYMOL LAB, ORSAY, FRANCE
关键词
D O I
10.1111/j.1423-0410.1996.tb01327.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intravenous immunoglobulins (IVIg) purified by cold ethanol fractionation have a very good safety record with regard to the transmission of many viruses. However, a few cases of non-A-non-B hepatitis have been described after intravenous injection of some immunoglobulin preparations. To ensure even higher safety for our IVIg, an additional virus inactivation step, based on pasteurization, was developed. The heating of aqueous IVIg was performed without stabilizer, and at a very low salt concentration (<1 mM) at acidic pH. No generation of polymer was detected after pasteurization and a significant decrease in the proportion of dimers was observed. Analysis of the secondary structure by circular dichroism showed a very slight change in the secondary structure. The biological properties of the Fc region as well as the Fab region were not affected by the pasteurization. Our method has several advantages: (1) improvement of viral safety; (2) there is no need to add stabilizer which may stabilize viral particles, and (3) the absence of any hypotensive effect and low anticomplementary activity indicates a good clinical tolerance of IgG preparation.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 34 条
[1]  
Adler A J, 1973, Methods Enzymol, V27, P675
[2]  
ALVING BM, 1980, J LAB CLIN MED, V96, P334
[3]   HYPOTENSION ASSOCIATED WITH PREKALLIKREIN ACTIVATOR (HAGEMAN-FACTOR FRAGMENTS) IN PLASMA-PROTEIN FRACTION [J].
ALVING, BM ;
HOJIMA, Y ;
PISANO, JJ ;
MASON, BL ;
BUCKINGHAM, RE ;
MOZEN, MM ;
FINLAYSON, JS .
NEW ENGLAND JOURNAL OF MEDICINE, 1978, 299 (02) :66-70
[4]  
*ASS FRANC NORM, 1989, DET VIR ACT BACT, P4
[5]   INTRAVENOUS ADMINISTRATION OF HUMAN GAMMA-GLOBULIN [J].
BARANDUN, S ;
JEUNET, F ;
KISTLER, P ;
ISLIKER, H .
VOX SANGUINIS, 1962, 7 (02) :157-&
[6]  
BARRETT PN, 1986, VIRUSINAKTIVIERUNG B
[7]  
BERKMAN SA, 1988, SEMIN HEMATOL, V25, P140
[8]   1ST DETERMINATION OF THE SECONDARY STRUCTURE OF PURIFIED FACTOR-VIII LIGHT CHAIN [J].
BIHOREAU, N ;
FONTAINEAUPART, MP ;
LEHEGARAT, A ;
DESMADRIL, M ;
YON, JM .
BIOCHEMICAL JOURNAL, 1992, 288 :35-40
[9]   AN ANIMAL-MODEL FOR THE DETECTION OF HYPOTENSIVE SIDE-EFFECTS OF IMMUNOGLOBULIN PREPARATIONS [J].
BLEEKER, WK ;
AGTERBERG, J ;
RIGTER, G ;
DEVRIESVANROSSEN, A ;
BAKKER, JC .
VOX SANGUINIS, 1987, 52 (04) :281-290
[10]  
CHRISTIAN CL, 1960, J IMMUNOL, V84, P112